Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
$13.15
+2.7%
$10.58
$5.67
$13.35
$250.17M1.467,672 shs33,240 shs
PAVmed Inc. stock logo
PAVM
PAVmed
$0.60
+1.0%
$0.66
$0.55
$1.90
$10.21M1.06135,585 shs19,874 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$47.71
+5.9%
$45.21
$17.02
$70.26
$155.94M0.1935,964 shs27,791 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$31.65
-0.2%
$30.34
$5.17
$39.50
$270.79M1.24145,744 shs21,863 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
+2.73%+0.38%+29.05%+48.59%+121.75%
PAVmed Inc. stock logo
PAVM
PAVmed
+1.02%-3.38%-0.42%+0.34%-15.68%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
+5.90%+10.67%+11.52%-6.27%+178.52%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-0.22%-4.21%+11.76%+3.20%+3,164,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
1.1327 of 5 stars
1.53.00.00.00.60.81.9
PAVmed Inc. stock logo
PAVM
PAVmed
3.9591 of 5 stars
3.55.00.04.30.00.01.9
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
2.4598 of 5 stars
2.52.00.00.02.61.71.9
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
3.00
Buy$14.258.37% Upside
PAVmed Inc. stock logo
PAVM
PAVmed
3.00
Buy$19.003,082.58% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
3.00
Buy$56.0017.38% Upside
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PAVM, SNWV, BWAY, and PDEX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/6/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.50 ➝ $19.00
5/27/2025
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$54.00 ➝ $56.00
4/21/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $19.50
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
$41.02M6.06$0.25 per share53.10$3.31 per share3.97
PAVmed Inc. stock logo
PAVM
PAVmed
$2.99M3.41N/AN/A($0.92) per share-0.65
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$53.84M2.89$0.96 per share49.94$9.03 per share5.28
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$32.63M8.30N/AN/A($1.49) per share-21.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
$2.92M$0.2065.7582.19N/A9.01%7.35%4.72%8/5/2025 (Estimated)
PAVmed Inc. stock logo
PAVM
PAVmed
$39.79M$0.710.84N/AN/A3,711.54%N/A-42.29%8/12/2025 (Estimated)
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$2.13M$2.8017.0423.16N/A14.61%29.08%16.19%9/4/2025 (Estimated)
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$4.56N/AN/A-89.86%N/A-145.76%N/A

Latest PAVM, SNWV, BWAY, and PDEX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
$0.02$0.04+$0.02$0.04$11.45 million$11.54 million
5/9/2025Q1 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A-$0.66N/A-$0.66N/A$9.34 million
5/1/2025Q3 2025
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$0.47$0.98+$0.51$0.98$17.70 million$17.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
N/A
5.03
4.75
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.37
0.37
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.28
2.73
1.45
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.40
0.28

Institutional Ownership

CompanyInstitutional Ownership
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
30.11%
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%

Insider Ownership

CompanyInsider Ownership
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
19.00%
PAVmed Inc. stock logo
PAVM
PAVmed
7.30%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
47.50%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
36.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
12018.90 million15.31 millionNot Optionable
PAVmed Inc. stock logo
PAVM
PAVmed
9017.09 million15.85 millionOptionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1403.26 million1.71 millionNot Optionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.56 million5.43 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Brainsway stock logo

Brainsway NASDAQ:BWAY

$13.15 +0.35 (+2.73%)
As of 07/3/2025 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

PAVmed stock logo

PAVmed NASDAQ:PAVM

$0.60 +0.01 (+1.02%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$0.60 0.00 (0.00%)
As of 07/3/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Pro-Dex stock logo

Pro-Dex NASDAQ:PDEX

$47.71 +2.66 (+5.90%)
As of 07/3/2025 03:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$31.65 -0.07 (-0.22%)
As of 07/3/2025 01:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.